Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.

BSA Behavioral Health announced it is expanding its mental health services to include Spravato (esketamine) nasal spray, for ...

RISE Integrated Mental Health in York, Maine, offers ketamine therapy for trauma and depression, attracting patients ...

Market reaction to recent readouts from Compass Pathways and Beckley Psytech/atai in treatment-resistant depression speaks to ...

We need a resurgence of enthusiasm and encouragement for those able to develop alternative and more effective treatments, so ...

Esketamine, a form of ketamine taken as a nasal spray, has been approved for the treatment for moderate to severe treatment-resistant depression in Scotland but intravenous ketamine has not, though it ...

Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Officer following previously announced ...

Florida is stepping up its efforts to help abate veteran suicide by agreeing to spend $300,000 this year to expand statewide ...

More than thirty years since its 1993 founding, Catherine Owen Adams and Elizabeth Thompson—the R&D combo that has led Acadia ...

Atai Life Sciences is making incremental progress towards opening door for a first psychedelic treatment for depression. Read ...

When Matt Thierfelder began his career as a Vancouver firefighter in 1994, the weight of unspoken rules hung over him: Don’t show weakness and don’t be vulnerable.